Clinical Trial: Randomized Split-Face Controlled Study to Evaluate the Effectiveness of Topical Eflornithine 9.58% + Hydroquinone 4% + Fluocinolone 0.01% as Compared to Topical Tretinoin 0.05% + Hydroquinone 4% + Fluocinolone 0.01% for the Treatment of Melasma

U.S., Oct. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07876323) titled 'Randomized Split-Face Controlled Study to Evaluate the Effectiveness of Topical Eflornithine 9.58% + Hydroquinone 4% + Fluocinolone 0.01% as Compared to Topical Tretinoin 0.05% + Hydroquinone 4% + Fluocinolone 0.01% for the Treatment of Melasma' on Oct. 09.

Brief Summary: The purpose of this study is to find out whether a new combination cream containing eflornithine, hydroquinone, and fluocinolone works better and causes fewer side effects than Tri-Luma(R) (tretinoin, hydroquinone, and fluocinolone), a commonly used treatment for melasma.

The main question is whether replacing tretinoin in Tri-Luma(R) with eflornithine leads to gr...